Stock Alert for Sunpeaks Ventures Inc. (SNPK)
  • Stock Alert for Sunpeaks Ventures Inc. (SNPK)
  • Stock Alert for Sunpeaks Ventures Inc. (SNPK)
  • " />

    Penny Stock Spotlight: Sunpeaks Ventures Inc. (SNPK)

    Penny Stock Spotlight: Sunpeaks Ventures Inc. (SNPK)

    Shares of Sunpeaks Ventures Inc. (OTCBB: SNPK) rose 38.37% to close Friday’s traded at $0.60, extending gains from the previous session, with volume of over 98.71 million shares traded.

    Sunpeaks, together with its wholly owned subsidiary Healthcare Distribution Specialists LLC (HDS), is a nationally focused, value-added distributor of specialty drugs and over-the-counter (OTC) branded multivitamins to the healthcare provider market.

    The company in February completed its acquisition of HDS, which owns and markets Clotamin, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin, a popular blood thinner that has a long list of known adverse drug and food interactions. HDS currently serves the secondary segment of the specialty drug market, estimated by management to be a $45 billion market segment. HDS functions as a just-in-time source of supply for hospitals for those products that are hard-to-find due to drug manufacturers’ production shortages.

    Sunpeaks is currently analyzing several OTC products that would allow the company to become a powerful OTC player in the multibillon dollar health supplement market.

    The company recently announced that it has reached final stages of negotiations to engage a well-known sports celebrity to act as national spokesperson for its Clotamin product. Mackie Barch, CEO of SNPK, commented in the release: “We couldn’t be happier about identifying a current Clotamin user who also happens to be a legendary player and coach in the NBA. We believe that a strong marketing campaign featuring this individual could really help to boost Clotamin awareness and sales across the board.”

    Last week, Sunpeaks provided an update regarding the development and market potential of Clotamin, which it claims to be the world’s first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin or other anticoagulants (blood thinners). According Barch, if Sunpeaks is able to penetrate just 5% of the market for Warfarin, which is one of the top 20 most prescribed drugs in the U.S. —  with over 32 million prescriptions being written each year for about 6 to 7 million patients,  Clotamin sales could potentially surpass $25 million annually. The company looks forward to ramping up its marketing and distribution efforts over the next few weeks and increasing awareness of Clotamin nationwide.

    Also last week, the company announced its cancellation of 50 million common shares of its authorized stock, with the intent of improving its overall capital structure and to increase shareholder value.

    Leave a Reply

    Your email address will not be published. Required fields are marked *